AI Leading the Way to More Precise Diagnostics and Disease Risk Prediction
Inside Precision Medicine features our Chief Scientific Officer, Dr. Udo Hoffmann, on how AI has changed CT imaging and the TRANSFORM trial that may...
Only a few months after it emerged from stealth and burst onto the medtech scene, Cleerly is already living up to its name.
By Andrea Park
The newly published results of a study show that the New York City-based startup’s artificial intelligence-powered software does, indeed, allow healthcare providers to (ahem) clearly spot signs of heart disease without requiring the invasive evaluations that make up the current gold standard for coronary artery disease diagnosis.
In the latter method, the coronary angiogram, a catheter is threaded through the arm or leg to reach the heart, where it injects dye into its arteries so X-ray images can capture how blood flows through the vessels. Though serious complications from the procedure are rare, they potentially include injury to the catheterized artery, an allergic reaction or kidney damage from the dye, as well as heart attack, stroke and more. Read the full article HERE.
Inside Precision Medicine features our Chief Scientific Officer, Dr. Udo Hoffmann, on how AI has changed CT imaging and the TRANSFORM trial that may...
Selected from more than 10,000 private healthcare companies, Cleerly is named one of CB Insight’s Digital Health 50 based on R&D, Mosaic scores,...
Nasdaq interviews CEO Dr. James K. Min, one of their 18 “Brilliant Minds in Healthcare,” about Cleerly’s founding, his vision for the company, and...